Jefferies Raises CytomX Therapeutics (CTMX) Price Target to $16

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is among the 11 Most Active Small Cap Stocks to Buy. On March 18, CytomX Therapeutics, Inc. (NASDAQ:CTMX) saw Jefferies raise its price target to $16 from $8 while maintaining a Buy rating following encouraging Phase 1 data for its lead asset Varseta-M in late-line metastatic colorectal cancer. The analyst highlighted the therapy’s potential as a differentiated antibody-drug conjugate (ADC), estimating a commercial opportunity exceeding $1 billion in later-line sett ...